JFL Life SciencesNSE:JFLLIFE 65 EBITDA Margin % is 9.90% as of Mar. 2025, which is at its 10-year median of 9.90. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 65/100 and a GF Value™ of ₹35.55 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, JFL Life Sciences ranks worse than 56.34% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. JFL Life Sciences's EBITDA for the
six
months ended in Mar. 2025 was ₹81.2 Mil. JFL Life Sciences's Revenue for the
six
months ended in Mar. 2025 was ₹820.4 Mil. Therefore, JFL Life Sciences's EBITDA margin for the quarter that ended in Mar. 2025 was 9.90%.
JFL Life Sciences (NSE:JFLLIFE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
JFL Life Sciences EBITDA Margin % Related Terms
JFL Life Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JFL Life Sciences (NSE:JFLLIFE) has a EBITDA Margin % of 9.90% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JFL Life Sciences and its competitors. This is near median its historical median of 9.90. Over the past decade, JFL Life Sciences' EBITDA Margin % has ranged from 3.80 to 18.52. According to the industry distribution chart, JFL Life Sciences ranks #538 out of 955 companies in the Drug Manufacturers industry, placing it in the top 56.3%.
Is JFL Life Sciences' EBITDA Margin % too high?
JFL Life Sciences' current EBITDA Margin % of 9.90% is near median its 10-year median of 9.90. Over the past 10 years, this metric has ranged from a low of 3.80 to a high of 18.52. The Drug Manufacturers industry median EBITDA Margin % is 12.44. JFL Life Sciences' value of 9.90% is 20.4% below this industry median. Based on the distribution chart, JFL Life Sciences ranks #538 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, JFL Life Sciences has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #538 out of 955 companies for EBITDA Margin %. This places JFL Life Sciences in the lower half of its industry. The industry median EBITDA Margin % is 12.44. JFL Life Sciences' value of 9.90% is 20.4% below this benchmark. Historically, JFL Life Sciences' own EBITDA Margin % has ranged from 3.80 to 18.52 over the past decade. While the company's 10-year median is 9.90 vs. the industry median of 12.44, JFL Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current EBITDA Margin % of 9.90% is 20.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current EBITDA Margin % is 9.90%, which is near median its own 10-year median of 9.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.55, compared to a current price of ₹9.05 — trading 74.5% below its estimated fair value. The current EBITDA Margin % is 9.90%, which is near median its 10-year median of 9.90 and 20.4% below the Drug Manufacturers industry median of 12.44. JFL Life Sciences' overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current EBITDA Margin % is 9.90% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹9.05 is trading 74.5% below its estimated GF Value™ of ₹35.55.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
EBITDA Margin %: 9.90% (near median its 10-year median of 9.90)
GF Value™: ₹35.55 vs. price of ₹9.05 (74.5% below fair value)
Industry Position: 20.4% below the Drug Manufacturers median (#538 of 955)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
65GF Score
Get the complete analysis for NSE:JFLLIFE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 